Update date
31 Dec 2025
Shareable Research Card
ASND - Ascendis Pharma A/S Liabilities
This metric view shows ASND - Ascendis Pharma A/S liabilities history from SEC company facts.
Use it to verify the latest reported value, compare nearby periods, and jump to a cross-company ranking when a curated insight exists.
- Context
- Latest reported period: Q4 2025
- Latest reported value
- €1,465,391,000
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Values may differ by reporting period and company taxonomy.
Return Loop
Why revisit this metric view
This metric history becomes more useful after the next quarterly or annual filing because the latest reported value, period, and company comparison context can all change.
- Latest source-backed update
- Latest period end 31 Dec 2025
- Why come back
- Return after the next filing to verify whether this metric changed and how it compares with the ranking page.
- Current latest reported period: Q4 2025.
- Latest reported value on this page: €1,465,391,000.
- Save this filer if you want to compare the next reported value with this history.
Metric freshness comes from the latest SEC company fact available for this taxonomy tag and the paired company facts page.
Latest update
Latest update for Liabilities
Latest reported liabilities: €1,465,391,000. Open the source-backed page to compare this metric with the newest filing-backed context.
Page type
Metric history
Latest period
Q4 2025
SEC-backed company facts were refreshed from filings filed on 11 Feb 2026.
Benchmark Context
How Liabilities compares with peers
Ascendis Pharma A/S sits in the upper half of the current liabilities sample.
Compared with
Compared with 55 companies reporting liabilities in EUR. This keeps the comparison on the same metric and unit family.
Why this is notable
This is about 1.4x the current sample midpoint. Liabilities is up about 14% versus the comparable prior period.
- Visible rows currently span reported period ends from 31 Dec 2021 to 31 Dec 2025.
- Nearby companies in this sample: Sportradar Group AG and Lakefront Biotherapeutics NV.
- Current sample position: rank #26 of 55 comparable companies.
- Peer rows use the latest valid value per company for this exact metric and compatible units.
Peer comparisons use the same metric and compatible units only. Latest reported periods may differ across companies, so open each company page before drawing conclusions.
Save this filer page
Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.
Financial Metric Page
Ascendis Pharma A/S: Liabilities
Latest period: Q4 2025. Period end: 31 Dec 2025. Units: EUR. Frequency: quarterly.
Liabilities is reported in company XBRL facts filed with the SEC.
Metric snapshot
- Latest value
- €1,465,391,000
- Coverage range
- 31 Mar 2021 - 31 Dec 2025
- Fact rows
- 20
What this metric tells you
- Shows reported liabilities over 31 Mar 2021 - 31 Dec 2025.
- Includes year-over-year change points to highlight acceleration or slowdown.
- Built from 20 SEC fact rows for this metric and issuer.
How to read this chart
- Start with the latest point, then compare it with the prior periods to see direction.
- Use quarterly sequence to compare like-for-like periods.
- Use YoY change bars to separate growth from contraction across matching periods.
Official SEC source
Source: SEC company facts
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Reporting periods may differ by company.
- View financial facts overview
- Ascendis Pharma A/S SEC filings
- Latest 10-Q/10-K hub
- Open SEC company facts
Direct filing link is shown only when a matched SEC filing document is available for this metric context.
Compare This Metric Across Companies
Compare latest available Liabilities levels across SEC-reporting companies, then open each company metric page for SEC-backed verification. Reporting periods may differ by company.
Ascendis Pharma A/S appears at rank #26 in the latest comparison sample.
| Rank | Company | Latest value | Report period | Next step |
|---|---|---|---|---|
| 1 | Banco Santander, S.A. (san) | €1,754,767,000,000 | Instant - 31 Dec 2025 | Open Banco Santander, S.A. Liabilities |
| 2 | DEUTSCHE BANK AKTIENGESELLSCHAFT (db) | €1,321,219,000,000 | Instant - 30 Jun 2025 | Open DEUTSCHE BANK AKTIENGESELLSCHAFT Liabilities |
| 3 | ING GROEP NV (ing) | €1,004,990,000,000 | Instant - 31 Dec 2025 | Open ING GROEP NV Liabilities |
| 4 | BANCO BILBAO VIZCAYA ARGENTARIA, S.A. (bbva) | €797,778,000,000 | Instant - 31 Dec 2025 | Open BANCO BILBAO VIZCAYA ARGENTARIA, S.A. Liabilities |
| 5 | AEGON LTD. (aeg) | €318,077,000,000 | Instant - 31 Dec 2024 | Open AEGON LTD. Liabilities |
| 6 | ENI SPA (e) | €84,282,000,000 | Instant - 31 Dec 2025 | Open ENI SPA Liabilities |
Metric Details
- Metric
- Liabilities (Liabilities)
- Frequency coverage
-
quarterly
Comparability: Compare annual with annual and quarterly with quarterly
- Taxonomy
- ifrs-full
- Units tracked
- EUR
- History range
-
31 Mar 2021 - 31 Dec 2025
Freshness: From parsed SEC XBRL facts on this page
- Facts on this page
-
20
Source: SEC company facts API
- SEC metric endpoint
- Open SEC company concept
Metric identity
Names, identifiers, and filing context for this profile.
1 identity field
Metric coverage
3 source fields
Source evidence
Original filing metadata and source links for verification.
1 source field
Chart Context
Compare periods with the same frequency first, then use YoY and TTM series to confirm whether changes are structural or one-off.
Liabilities, Quarterly (EUR)
Liabilities, YoY Quarterly Change (%)
Ascendis Pharma A/S Quarterly Liabilities (EUR)
| Period | Value | YoY Chg | Change % | Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | €1,465,391,000 | +€180,190,000 | +14% | 31 Dec 2025 | 20-F | 11 Feb 2026 | 2025 | FY |
| Q3 2025 | €1,328,825,000 | +€137,722,000 | +12% | 30 Sep 2025 | 6-K | 12 Nov 2025 | 2025 | Q3 |
| Q2 2025 | €1,275,474,000 | +€196,043,000 | +18% | 30 Jun 2025 | 6-K | 07 Aug 2025 | 2025 | Q2 |
| Q1 2025 | €1,251,245,000 | +€210,562,000 | +20% | 31 Mar 2025 | 6-K | 01 May 2025 | 2025 | Q1 |
| Q4 2024 | €1,285,201,000 | +€313,917,000 | +32% | 31 Dec 2024 | 20-F | 11 Feb 2026 | 2025 | FY |
| Q3 2024 | €1,191,103,000 | +€244,457,000 | +26% | 30 Sep 2024 | 6-K | 14 Nov 2024 | 2024 | Q3 |
| Q2 2024 | €1,079,431,000 | +€320,449,000 | +42% | 30 Jun 2024 | 6-K | 03 Sep 2024 | 2024 | Q2 |
| Q1 2024 | €1,040,683,000 | +€241,610,000 | +30% | 31 Mar 2024 | 6-K | 02 May 2024 | 2024 | Q1 |
| Q4 2023 | €971,284,000 | +€144,894,000 | +18% | 31 Dec 2023 | 20-F | 12 Feb 2025 | 2024 | FY |
| Q3 2023 | €946,646,000 | +€124,778,000 | +15% | 30 Sep 2023 | 6-K | 07 Nov 2023 | 2023 | Q3 |
| Q2 2023 | €758,982,000 | +€39,993,000 | +5.6% | 30 Jun 2023 | 6-K | 05 Sep 2023 | 2023 | Q2 |
| Q1 2023 | €799,073,000 | +€94,639,000 | +13% | 31 Mar 2023 | 6-K | 27 Apr 2023 | 2023 | Q1 |
| Q4 2022 | €826,390,000 | +€625,104,000 | +311% | 31 Dec 2022 | 20-F | 07 Feb 2024 | 2023 | FY |
| Q3 2022 | €821,868,000 | +€610,197,000 | +288% | 30 Sep 2022 | 6-K | 02 Nov 2022 | 2022 | Q3 |
| Q2 2022 | €718,989,000 | +€554,628,000 | +337% | 30 Jun 2022 | 6-K | 10 Aug 2022 | 2022 | Q2 |
| Q1 2022 | €704,434,000 | +€541,940,000 | +334% | 31 Mar 2022 | 6-K | 11 May 2022 | 2022 | Q1 |
| Q4 2021 | €201,286,000 | +€60,204,000 | +43% | 31 Dec 2021 | 20-F | 16 Feb 2023 | 2022 | FY |
| Q3 2021 | €211,671,000 | +€117,132,000 | +124% | 30 Sep 2021 | 6-K | 10 Nov 2021 | 2021 | Q3 |
| Q2 2021 | €164,361,000 | +€80,898,000 | +97% | 30 Jun 2021 | 6-K | 27 Aug 2021 | 2021 | Q2 |
| Q1 2021 | €162,494,000 | +€89,919,000 | +124% | 31 Mar 2021 | 6-K | 27 May 2021 | 2021 | Q1 |
* marks a reported value that did not pass the local value check.